From the Journals

Metformin linked with better survival in RCC patients with diabetes


 

Metformin use was associated with better survival for patients with renal cell carcinoma and diabetes in a meta-analysis, investigators report.

However, there was significant heterogeneity among the eight eligible studies included in the meta-analysis, Dr. Li and associates reported (Int Urol Nephrol. 2017 Mar 7. doi: 10.1007/s11255-017-1548-4).

In a subgroup analysis, the association held in patients with localized disease, but was not significant in those with metastatic disease.

The current meta-analysis suggests that the use of metformin could improve the survival of kidney cancer patients, particularly those with localized disease; however, further studies are needed, the investigators conclude.

The authors declared that they had no conflicts of interest.

Recommended Reading

Genetics dictate interferon-alfa diarrhea risk
MDedge Hematology and Oncology
AKT inhibition not superior to everolimus for RCC
MDedge Hematology and Oncology
ASCO offers practice guidance on small renal masses
MDedge Hematology and Oncology
Intermittent breaks from sunitinib feasible in metastatic RCC
MDedge Hematology and Oncology
Cabozantinib versus everolimus in advanced RCC with bone mets
MDedge Hematology and Oncology
Staying the course after first progression yields better mRCC survival
MDedge Hematology and Oncology
Clinical benefit persists for some with mRCC after stopping immune checkpoint blockade
MDedge Hematology and Oncology
Genomic differences seen in mRCC during first- and second-line therapy
MDedge Hematology and Oncology
No benefit from adjuvant sunitinib or sorafenib for clear cell renal cancer
MDedge Hematology and Oncology
Current Therapeutic Approaches to Renal Cell Carcinoma
MDedge Hematology and Oncology